Brought to you by
ECR 2019 / C-0185
Certificate of Merit
Neurooncology pending battles: is it possible to differentiate true progression from pseudoprogression?
Congress: ECR 2019
Poster No.: C-0185
Type: Educational Exhibit
Keywords: Neoplasia, Multidisciplinary cancer care, Radiation effects, Diagnostic procedure, MR-Diffusion/Perfusion, MR, Neuroradiology brain
Authors: A. Hilario Barrio, P. Martín Medina, E. Salvador, G. Ayala, L. Koren, A. Martinez de Aragon, F. Ballenilla, J. M. Millan, A. Ramos Gonzalez; Madrid/ES
DOI:10.26044/ecr2019/C-0185

References

1. Hygino da Cruz Jr LC, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma. AJNR 2011;32:1978-85

2. Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence. AJNR Am J Neuroradiol 2015;36:877-85.

3. Yun TJ, Park C-K, Kim TM, Lee S-H, Sohn C-H, Park S-H. Glioblastoma treated with Concurrent Radiation Therapy and Temozolomide Chemotheraphy. Radiology 2015;274(3):830-40.

4. Boxerman JL, Ellingson BM, Jeyapalan S, Elinzano H, Harris RJ, Rogg JM, et al. Longitudinal DSC-MRI for distinguishing Tumor Recurrence from Pseudoprogression in Patients with High-grade Glioma. Am J Clin Oncol 2017;40:228-34.

5. Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neuroncol 2015;125:183-90.

6. Yoo R-E, Choi SH, kim TM, Lee S-H, Park C-K, Park S-H, et al. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value. AJNR Am J Neuroradiol 2015;36:1846-52.

7. Yoo R-E, Choi SH. Recent Application of Advances MR Imaging to Predict Pseudoprogression in High-Grade Glioma Patients. Magn Reson Med Sci 2016;15(2):165-77.

8. Abdulla S, Saada J, Johnson G, Jefferies S, Ajithkumar T. Tumor progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. Clinical Radiology 2015;70:1299-1312.

9. Galldiks N, Kocher M, Langen K-J. Pseudoprogression after glioma therapy: an update. Expert Review of Neurotherapeutics 2017;17(11):1109-15.

10. Yoon RG, Kin HS, Paik W, Shim WH, Kim Sj, Kim JH. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation. Eur Radiol 2017;27:255-66.

11. Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, et al. Differentiating Tumor Progerssion from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. AJNR Am J Neuroradiol 2016;37:28-36.

12. Patel P, Barandaran H, Delgado D, Askin G, Christos P, Tsiouris AJ. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol 2017;19(1):118-27.

13. Dalesandro MF, Andre JB. Posttreatment Evaluation of Brain Gliomas. Neuroimaging Clin N Am 2016;26:581-599.

14. Boxerman JL, Shiroishi MS, Ellingson BM, Pope WB. Dynamic Susceptibility Contrast MR Imaging in Glioma. Review of Current Clinical Practice. Magn Reson Imaging Clin N Am 2016;24:649-70.

15. Khalifa J, Tensaoutti F, Chaltiel L, Lotterie J-A, Catalaa I, Sunyach MP, et al. Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation. Eur Radiol 2016;26:4194-203.

16. Chang PD, Chow DS, Yang PH, Filippi CG, Lignelli A. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Difussion Coefficient Value and Signal Intensiy in FLAIR Images. AJR 2017;208:57-65.

17. Liu Z-C, Yan L-F, Hu Y-C, Sun Y-Z, Tian Q, Nan H-Y, et al. Combination of IVIM-DWI and 3D-ASl for differentiating true progression from pseudoprogression of glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial. BMC Medical Imaging 2017;17:10.

18. Nandu H, Wen PY, Huang RY. Imaging in neuro-oncology. Ther Adv Neurol Disord 2018;11:1-19.

19. Chian GC, Kovanlikaya I, Choi C, Ramakrishna R, Magge R, Shungu DC. Magnetic Resonance Spectroscopy. Positron Emission Tomography and Radiogenomics-Relevance to Glioma. Frontiers in Neurology 2018;9(33).

20. Lincoln CM, Fata P, Sotardi S, Pohlen M, Uribe T, Bello JA. Imaging Spectrum of immunomodulating, chemotherapeutic and radiation therapy-related intracranial effects. Br J Radiol 2017;90.

21. Wen PY, Chang SM, Van den Bent J, Vogelbaum MA, Macdonald DR, Lee EQ: Response Assessment in Neuro-Oncology Clinical Trials. J Clin Oncol 2017;35:2439-2449.

22. Kahn MN, Sharma AM, Pitz M, Loewen Sk, Quon H, Poulin A, et al. High-grade glioma management and response assessment-recent advances and current challenges. Curr Oncol 2016;23(4):e383-e391.

23. Wan B, Wang S, Tu M, Wu B, Han P, Xu H. The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression. Medicine 2017;96:11.

24. Hyare H, Thust S, Rees J. Advanced MRI Techniques in the Monitoring of Treatment of Gliomas. Curr Treat Options Neurol 2017;19:11.

25. Fatterpekar GM, Galheigo D, Narayana A, Johnson G, Knopp E. Treatment-Related Change Versus Tumor Recurrence in High-Grade Gliomas: A Diagnostic Conundrum - Use of Dynamic Susceptibility Contrast-Enhanced (DSC) Perfusion MRI. AJR 2012;198:19-26.

 

POSTER ACTIONS Add bookmark Contact presenter Send to a friend Download pdf
SHARE THIS POSTER
2 clicks for more privacy: On the first click the button will be activated and you can then share the poster with a second click.

This website uses cookies. Learn more